The IMF’s Understanding series of cancer information booklets is designed to acquaint you with specific multiple myeloma-related tests, treatments and therapies, supportive care measures, and common adverse events.
August 01, 2023
Full of our informative publications, including our Patient Handbook and selections from the popular Understanding Series, the Info Pack will…
Link
July 01, 2024
Immunotherapy with Abecma® (idecabtagene vicleucel or “ide-cel” for short) is FDA-approved for the treatment of relapsed refractory multiple myeloma…
May 07, 2024
Carvykti® (ciltacabtagene autoleucel, or “cilta-cel” for short) is a customized immunotherapy approved by the FDA for the treatment of patients…
September 02, 2024
This booklet serves as an introduction to cereblon E3 ligase modulatory drugs (CELMoDs), a new class of medications currently being studied in…
September 20, 2023
This publication discusses what myeloma patients should consider if enrolling in a clinical trial.
with support from:
Johnson & Johnson and Pfizer.